 "AstraZeneca resumes US Covid-19 vaccine trial, optimism seen for J&J")
AstraZeneca Plc has resumed the US trial of its experimental Covid-19 vaccine after approval by US regulators, the company said on Friday.
AstraZeneca's US trial was paused on September 6 after a report of a serious neurological illness, believed to be transverse myelitis, in a participant in the company's UK trial.
US Health and Human Services Deputy Chief of Staff Paul Mango also told reporters he was optimistic a US trial by Johnson & Johnson would resume.
J&J paused its large, late-stage trial last week after a study participant became ill and the company said an independent safety panel was investigating.
AstraZeneca trials in the United Kingdom, Brazil and South Africa resumed last month even as the US Food and Drug Administration continued its investigation into the case.
Reuters earlier this week reported that the FDA had completed its review and that the AstraZeneca US trial was set to resume as early as this week, citing four sources familiar with the situation.
AstraZeneca's vaccine is being developed along with researchers at Oxford University.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%